Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02551263
What this trial is testing

Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 201
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Large-scale testing (Phase 3)UnknownNCT06857305
What this trial is testing

Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

Who this might be right for
Breast Cancer Metastatic
Ma Fei，MD 192
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05476796
What this trial is testing

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Who this might be right for
Gastric AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Junction Adenocarcinoma
UNICANCER 118
Not applicableStudy completedNCT03719833
What this trial is testing

Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents

Who this might be right for
Breast CancerSentinel Lymph Node BiopsyNeoadjuvant Chemotherapy
Clinical Hospital Center Rijeka 230
Large-scale testing (Phase 3)Active Not RecruitingNCT06065748
What this trial is testing

Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche 1,050
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07801898
What this trial is testing

Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

Who this might be right for
Invasive Breast Cancer (Stage I-III)
The Second Hospital of Anhui Medical University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06874933
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 35
Not applicableStudy completedNCT02269813
What this trial is testing

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 452
Testing effectiveness (Phase 2)Looking for participantsNCT05535413
What this trial is testing

UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Who this might be right for
Metastatic HER2 Negative Breast CarcinomaBrain MetastasesCapecitabine+1 more
Hunan Cancer Hospital 30
Not applicableUnknownNCT03790813
What this trial is testing

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 50
Not applicableStudy completedNCT01928186
What this trial is testing

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more
University of Washington 28
Testing effectiveness (Phase 2)Study completedNCT00196820
What this trial is testing

Mono Efficacy of Capecitabine (MoniCa)

Who this might be right for
Breast Cancer
GBG Forschungs GmbH 200
Post-approval studies (Phase 4)Ended earlyNCT02688803
What this trial is testing

Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)

Who this might be right for
Breast Cancer
Ottawa Hospital Research Institute 2
Testing effectiveness (Phase 2)Looking for participantsNCT07276880
What this trial is testing

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer (TNBC)HER2-Negative Breast Carcinoma+1 more
UNC Lineberger Comprehensive Cancer Center 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07217990
What this trial is testing

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerTriple Negative Breast Cancer
Ohio State University Comprehensive Cancer Center 84
Not applicableLooking for participantsNCT06711055
What this trial is testing

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 285
Next Page